Kono Chem Co.,Ltd

Glutathione, Astaxanthin, Resveratrol, Quercetin, Rutin and other APIs

Product Certification

Kono Chem Co.,Ltd

Country:China (Mainland)

Business Type:Other

Assessed supplierAssessed
supplier

qq

    x
  • Mr.Sam
  • Ms.Sarah
  • Mr.Edward

Contacts

  • Mr.Hong
    Tel: 86-29-86107037-8015

  • Mr.Sam
    Tel: 86-29-86107037-8016

  • Ms.Sarah
    Tel: 86-29-86107037-8019

  • Mr.Edward
    Tel: 86-29-86107037-8021

  • Ms.Freya
    Tel: +86 29 86107037-8010

  • Ms.Jessica
    Tel: 029-86107037-8014

  • Mr.Gao
    Tel: +8613289246953

  • Fax: 86-29-81330164
  • URL: http://www.konochem.com
  • Province/state: Shaanxi
  • City: Xi'an
  • Street:No.11 Daqing Road,Lianhu District,Xi’an 710082,China
E-MAIL Supplier    Clike here
Home > Products > 

Reputable Factory Supply 155206-00-1 with Reasonable Price Bimatoprost

Reputable Factory Supply 155206-00-1 with Reasonable Price Bimatoprost CAS NO.155206-00-1

  • Min.Order: 1 Gram
  • Payment Terms: L/C,D/A,D/P,T/T,Other
  • Product Details

Keywords

  • Bimatoprost supplier
  • Bimatoprost manufacturer
  • 155206-00-1

Quick Details

  • ProName: Bimatoprost supplier 155206-00-1 manu...
  • CasNo: 155206-00-1
  • Molecular Formula: C25H37NO4
  • Appearance: white powder
  • Application: pharam
  • DeliveryTime: within 3 days
  • PackAge: Drum & Bag
  • Port: shanghai
  • ProductionCapacity: 1000 Gram/Day
  • Purity: ≥99.0 %
  • Storage: cool, dark
  • Transportation: by sea or air
  • LimitNum: 1 Gram
  • Related Substances: NMT 0.1%
  • Residue on Ignition: NMT 0.1%
  • Heavy Metal: 10PPM
  • Valid Period: 2 YEARS
  • CAS: 155206-00-1

Superiority

Bimatoprost CAS 155206-00-1

Bimatoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. Bimatoprost is manufactured at Cayman Pharma, our Czech subsidiary. The DMF is on file with the US FDA, Canada, and India.

Bimatoprost is a synthetic amide F2α derivative ,it can selectively simulate the effect forefront amines produced by the body, which make aqueous humor production rate increase aqueous outflow resistance is reduced, by increasing the amount of aqueous outflow of the uveoscleral and trabecular Netcom channel to reduce intraocular pressure (IOP),it is considered to be the most effective hypotensive drug of topical ocular anti-glaucoma drugs,it is suitable for the treatment of open-angle glaucoma (POAG) or invalid elevated intraocular other ocular hypotensive medications compression syndrome (OHT) patients.

Details

A potent prostanoid receptor (FP) agonist and PGF2α analog. Its biological activity is mediated by action on prostamide receptors. Has therapeutic potential for glaucoma and ocular hypertension.

Catalogue Number B386800
Chemical Name Bimatoprost
Synonyms (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide; AGN-192024; Lumigan; Prostamide;
CAS Number 155206-00-1
Molecular Formula C??H??NO?
Appearance White to Off-White Solid
Melting Point 64 - 65°C
Molecular Weight 415.57
Storage Amber Vial, -20°C Freezer, Under Inert Atmosphere
Solubility Chloroform (Slightly), Dichloromethane (Slightly), Methanol (Slightly)
Stability Light Sensitive
Category Standards; Chiral Molecules; Pharmaceutical/API Drug Impurities/Metabolites;
Applications Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α.

Reputable Factory Supply 155206-00-1 with Reasonable Price

  • Molecular Formula:C25H37NO4
  • Molecular Weight:415.573
  • Appearance/Colour:crystalline solid 
  • Vapor Pressure:9.94E-17mmHg at 25°C 
  • Melting Point:66-68°C 
  • Refractive Index:1.591 
  • Boiling Point:629.8 ºC at 760 mmHg 
  • PKA:14.25±0.20(Predicted) 
  • Flash Point:334.7 ºC 
  • PSA:89.79000 
  • Density:1.145 g/cm3 
  • LogP:3.53780 

Bimatoprost(Cas 155206-00-1) Usage

Glaucoma Drug

Bimatoprost is a synthetic amide F2α derivative ,it can selectively simulate the effect forefront amines produced by the body, which make aqueous humor production rate increase aqueous outflow resistance is reduced, by increasing the amount of aqueous outflow of the uveoscleral and trabecular Netcom channel to reduce intraocular pressure (IOP),it is considered to be the most effective hypotensive drug of topical ocular anti-glaucoma drugs,it is suitable for the treatment of open-angle glaucoma (POAG) or invalid elevated intraocular other ocular hypotensive medications compression syndrome (OHT) patients.

Side effects

1. to deepen the color of the iris, blepharitis, eye irritation and pain; black eyelashes thicker growth; conjunctival hyperemia, temporarily punctate corneal epithelial erosion, eyelid edema and erythema; rash. 2. rare respiratory disorders, asthma exacerbations, iritis, uveitis, eyelid skin darkening. 3. very rare chest pain, pharyngitis. 4. eye itching, allergic conjunctivitis, cataract, conjunctival edema, secretions, photophobia, superficial punctate keratitis, headache, high blood pressure.

Glaucoma commonly used drugs

1. prostaglandin derivatives such as latanoprost (Xalatan), bimatoprost (trade name Lumigan) and travoprost (Travatan) can increase outflow of aqueous humor uveoscleral . Bimatoprost also increases trabecular outflow. 2. topical β-adrenergic such as timolol, levobunolol (Betagan), and betaxolol can decrease receptor antagonist of aqueous humor production of ciliary body . 3. Alpha2-adrenergic agonists such as brimonidine (Alphagan) with dual working mechanism, can reduce aqueous humor production and increase trabecular outflow. 4. one case of the selective reduction similar to epinephrine and dipivefrin (Propine) increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway, probably by a β2-agonist action. 5. miotic agents (parasympathomimetics), if ciliary muscle contraction Roca works, it can tighten the trabecular and allow increaseing outflow of aqueous humor. Ecothiopate is used for chronic glaucoma. 6. dorzolamide (Trusopt), brinzolamide (Azopt), by inhibiting carbonic anhydrase acetazolamide of ciliary body, reduce aqueous humor secretion of carbonic anhydrase inhibitors. 7. Physostigmine is also used to treat glaucoma and delayed gastric emptying. The above information is edited by the lookchem of Tian Ye.

Bimatoprost - timolol maleate compound eye drops

In July 2006 , bimatoprost-timolol maleate compound eye drops developed by the United States company obtained approval from the European drug regulatory authority for reducing intraocular pressure or ocular hypertension of open-anglepatients glaucoma patients who do not respond adequately to the β-blockers or prostaglandin like treatment . The compound eye drops containing 0.03% bimatoprost and 0.5% timolol maleate, once a day administration is able to provide clinically effective pressure control, the effect is better than single Bima latanoprost or timolol maleate. Clinical trials prove that the drug has an excellent tolerability, including the incidence of ocular hyperemia40% lower compared to single bimatoprost .

Brand name

Lumigan (Allergan).

General Description

Bimatoprost (Lumigan) is supplied as a sterile 0.03%ophthalmic solution in 2.5- and 5.0-mL sizes. The recommendeddosage of bimatoprost is limited to one drop intothe affected eye once daily in the evening. Increased usagemay decrease its beneficial effect. If used concurrently withother IOP-lowering drugs, a waiting period of 5 minutesshould separate administrations.

InChI:InChI=1/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3+,17-16+/t20-,21+,22+,23-,24+/m0/s1

155206-00-1 Relevant articles

A new synthetic approach to prostaglandin analogues: Synthesis of bimatoprost via lipase enzymatic catalysis

Kamidi, Vijendhar,Kale, Pooja,Boodida, Sathyanarayana

, p. 2767 - 2770 (2017)

A simple, convenient and efficient synth...

Preparation method of bemeprost

-

Paragraph 0044; 0057-0059; 0060; 0073-0075; 0076; 0089-0091, (2021/03/06)

The invention discloses a preparation me...

Access to a Key Building Block for the Prostaglandin Family via Stereocontrolled Organocatalytic Baeyer–Villiger Oxidation

Zhu, Kejie,Hu, Sha,Liu, Minjie,Peng, Haihui,Chen, Fen-Er

supporting information, p. 9923 - 9927 (2019/05/16)

A new protocol for the construction of a...

PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE

-

, (2019/09/12)

The present invention relates to a proce...

Novel method for preparing Prostaglandin derivatives

-

Paragraph 0090; 0093; 0128-0130, (2017/10/31)

Provided is a novel method for preparing...

155206-00-1 Process route

(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol
856240-62-5

(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol

(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide
1201226-16-5

(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide

bimatoprost
155206-00-1

bimatoprost

Conditions
Conditions Yield
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 20 ℃; for 4h; Reagent/catalyst; Temperature; Inert atmosphere;
80%
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h;
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; In tetrahydrofuran; at 0 ℃;
65%
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 0 - 20 ℃; for 1h; Inert atmosphere;
41%
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 1h;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at -17 ℃; for 20.5h;
 
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Schlenk technique; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 20 ℃; for 1h; Schlenk technique; Inert atmosphere;
82.6 mg
(5-(ethylamino)-5-oxopentyl)triphenylphosphonium bromide; With potassium tert-butylate; In tetrahydrofuran; at 0 ℃; for 0.666667h; Inert atmosphere;
(3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol; In tetrahydrofuran; at 0 - 20 ℃; for 2h; Inert atmosphere;
108 mg
(5Z)-N-ethyl-7-((1R,2R,3R,5S)-5-hydroxy-2-((3S,E)-5-phenyl-3-(tetrahydro-2H-pyran-2-yloxy)pent-1-enyl)-3-(tetrahydro-2H-pyran-2-yloxy)cyclopentyl)hept-5-enamide
856240-52-3

(5Z)-N-ethyl-7-((1R,2R,3R,5S)-5-hydroxy-2-((3S,E)-5-phenyl-3-(tetrahydro-2H-pyran-2-yloxy)pent-1-enyl)-3-(tetrahydro-2H-pyran-2-yloxy)cyclopentyl)hept-5-enamide

bimatoprost
155206-00-1

bimatoprost

Conditions
Conditions Yield
With toluene-4-sulfonic acid; In methanol; at 20 ℃; for 2h;
77.5%
With toluene-4-sulfonic acid; In methanol; at 20 ℃; for 2h;
77.5%

155206-00-1 Upstream products

  • 75-04-7
    75-04-7

    ethylamine

  • 38315-47-8
    38315-47-8

    (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-(E)-3-hydroxy-5-phenylpent-1-enyl)-cyclopentyl]hept-5-enoic acid methyl ester

  • 856240-62-5
    856240-62-5

    (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol

  • 107-10-8
    107-10-8

    propylamine

155206-00-1 Downstream products

  • 1043914-34-6
    1043914-34-6

    C29H41NO7

  • 1163135-96-3
    1163135-96-3

    (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E)-3-oxo-5-phenylpent-1-en-1-yl]cyc!opentyl}-N-ethylhept-5-enamide

  • 1194047-71-6
    1194047-71-6

    (1R,2R,3R,4S)-3-[(2Z)-7-(ethylamino)-7-oxohept-2-en-1-yl]-4-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl 4-bromobutanoate

  • 1194047-69-2
    1194047-69-2

    4-chlorobutyl (2R,3R)-3-[(2Z)-7-(ethylamino)-7-oxohept-2-en-1-yl]-4-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl carbonate

Other products of this supplier

Kono Chem Co.,LtdTel:86-29-86107037-8015 Fax:86-29-81330164  Email:info@konochemical.com
 Address:No.11 Daqing Road,Lianhu District,Xi’an 710082,China,710082